Management of MDR and XDR TB [electronic resource] / Martin Boeree.
Material type:
FilmSeries: Henry Stewart talksBiomedical & life sciences collection. Respiratory infection: Publisher: London : Henry Stewart Talks, 2014Description: 1 online resource (1 streaming video file (34 min.) : color, sound)Other title: Management of multi-drug resistant and extensive drug resistant tuberculosisSubject(s): Antitubercular agents | International cooperation | Multidrug-resistant tuberculosis | Tuberculosis -- Chemotherapy | Tuberculosis -- Prevention | Antitubercular Agents -- pharmacology | Extensively Drug-Resistant Tuberculosis -- drug therapy | Extensively Drug-Resistant Tuberculosis -- prevention & control | International Cooperation | Tuberculosis -- drug therapy | Tuberculosis -- history | Tuberculosis -- prevention & control | Tuberculosis, Multidrug-Resistant -- drug therapy | Tuberculosis, Multidrug-Resistant -- prevention & controlOnline resources: Click here to access online | Series Animated audio-visual presentation with synchronized narration.
Title from title frames.
Contents: Management of multi drug resistance (MDR) and extensive drug resistance (XDR) TB -- Management of TB before era of drug treatment -- Surgery for TB -- Drug treatment was introduced from 1943-1963 -- Rifampicin (1963) -- Timeline: discovery of drugs for TB -- Emergence of totally drug resistant TB -- Epidemiology -- Outcomes of MDR-TB treatment -- Survival curve of HIV patients with XDR TB -- Current drug treatment -- Treatment outcome in several cohorts -- Death rates in several cohorts -- Current approach for treatment of MDR/XDR TB -- WHO's programmatic management of DR TB -- Treatment recommendations -- Group 1: oral first-line agents -- Group 2: fluoroquinolones -- Group 3: injectables -- Group 4: less-effective anti-TB drugs -- Group 5: less-effective or clinical data sparse drugs -- Future drug treatment -- New compounds -- Bedaquiline (TMC207) -- The nitroimidazoles -- Thioridazine -- NC-001 (PA-824, moxifloxacine, PZA) -- Dreams and realities for the future of TB treatment.
Access restricted to subscribers.
Mode of access: World Wide Web.